Unhealthy diets are driving digestive diseases, research suggests

Published Date: 04 Dec 2024

Against the backdrop of an alarming increase in the number of people under 50 being diagnosed with bowel cancer, researchers are urging people to bump up their fiber intake and improve their eating habits if they want to ...

Read Full News

Latest News

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs Brian Lacy, MD, PhD

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

News All Time

FDA Approves Freenome Blood Test for Colorectal Cancer Screening Alex Hillenbrand

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD Abigail Brooks, MA

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

How a Physician With Crohn's Disease Approaches IBD Care Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC Remo Panaccione, MD, FRCPC

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

6 Gastroenterology Headlines You Missed in August 2026 Alex Hillenbrand

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

TEV '408 Meets Primary Endpoint in Celiac Trial Alex Hillenbrand

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

43% Lower Mortality Seen in Colorectal Screening Participants Johannes Blom, MD, PhD

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer Alex Hillenbrand

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

C Diff Resistance to Bacitracin Reveals Potential Drug Target

C Diff Resistance to Bacitracin Reveals Potential Drug Target

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

A Life-Threatening Problem Hidden Within a Hiatal Hernia

Condition resolved after clinicians used a novel oral combination

Cirrhosis-Flagging Tool Stands Out for Steatotic Liver Disease in Primary Care

— SAFE outdid other risk scores in predicting 10-year cirrhosis risk

Recommended News For You

'Sleep ALL night' program helps children with leukemia sleep better during treatment

Q&A: Odds of surviving cancer drop drastically when credit score dips

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

For patients with breast cancer receiving chemotherapy, exercise may help lessen the long-term side effects.

Is Exercise an Effective Treatment for Prostate Cancer?

A novel blood test may enable the early identification of common, fatal cancers.

Two-part prodrug system activates immune attack only in tumor's unique environment

Recommended Articles For You

The Latest Advances in Glioblastoma Treatment and Prevention  

Functional Genomics of Treatment-Resistant Anemia 

ADCs and Bispecific Antibodies: Advancing the Future of Cancer Immunotherapy 

Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

2.

Clinical trial is testing whether heavy lifting could combat cancer side effects

3.

NIH research cuts leave cancer patient facing hard choice

4.

Nonmelanoma skin cancer has been linked to occupational exposure to solar UVR.

5.

A video animation guide to assist young people who are fatigued from cancer.

1.

Hematology Drug Preparation Safety: Ensuring Efficacy and Reducing Risks in Clinical Practice

2.

The Latest Advances in Glioblastoma Treatment and Prevention 

3.

AI-Assisted Real-Time Tumor Mapping During Surgery: Transforming Intraoperative Oncology

4.

Optimizing Platelet Transfusions: Balancing Benefits and Risks in Modern Hematology

5.

Decoding the Failures in Acute Myeloid Leukemia Treatment: Mechanisms, Pathways, & Survival Outcomes

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Understanding Anemia: Causes and Treatment

2.

Rates of CR/CRi and MRD Negativity in Iontuzumab-Treated Patients

3.

Optimizing Treatment Options in Advanced Urothelial Carcinoma

4.

Signs and Symptoms of Leukemia

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot